APDN Share Price | Applied DNA Sciences, Inc. Stock Analysis & Recommendation

Q: Is Applied DNA Sciences, Inc. technically bullish or bearish?

As of 19 August 2025, the technical trend for Applied DNA Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and monthly Bollinger Bands, both signaling bearish conditions. The MACD shows mildly bullish signals on the weekly and monthly time frames, but this is contradicted by the monthly RSI, which is bearish. Additionally, the Dow Theory indicates a bearish trend on the monthly scale. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -98.12% versus the S&P 500's 12.22%, highlighting a stark divergence in performance.

Q: What does Applied DNA Sciences, Inc. do?

Overview: Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.Financial Snapshot: Net Sales: 1 Million (Quarterly Results - Mar 2025) Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 2.45 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.61 Return on Equity: -122.44% Price to Book: 0.23Contact Details: Address: 50 Health Sciences Dr, STONY BROOK NY: 11790-3349 Tel: 1 631 2408800 Fax: 1 631 2408900 Website: http://www.adnas.com/

Q: Should I buy, sell or hold Applied DNA Sciences, Inc.?

Based on the current situation of Applied DNA Sciences, Inc., it would be advisable to consider selling your shares. The company is facing significant challenges, including operating losses and a weak long-term fundamental strength. The annual growth rate of operating profit has been negative at -13.58% over the past five years, indicating poor long-term growth prospects.Additionally, the company's ability to service its debt is concerning, with a poor EBIT to Interest ratio of -12.95. Recent financial results show the lowest operating cash flow at USD -13.26 million and a low inventory turnover ratio of 7.69%, which further highlights operational inefficiencies.Moreover, the stock is trading at risky levels compared to its historical valuations, and while it has generated a return of 0% over the past year, profits have only increased by 10.7%. Given these factors, selling seems to be the most prudent course of action at this time.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

793.39 k

Shareholding (Mar 2026)

FII

0.32%

Held by 11 FIIs

DII

94.01%

Held by 1 DIIs

Promoter

5.67%

Is Applied DNA Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Applied DNA Sciences, Inc. is in a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -98.12%.

View full answer

How big is Applied DNA Sciences, Inc.?

22-Jun-2025

As of Jun 18, Applied DNA Sciences, Inc. has a market capitalization of 2.45 million and reported net sales of 3.79 million with a net loss of 7.47 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 9.14 million and total assets of 12.79 million as of Sep 24.

View full answer

What does Applied DNA Sciences, Inc. do?

22-Jun-2025

Applied DNA Sciences, Inc. develops security solutions for the Pharmaceuticals & Biotechnology industry and has a market cap of $2.45 million. As of March 2025, it reported net sales of $1 million and a net loss of $3 million.

View full answer

Who are in the management team of Applied DNA Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Applied DNA Sciences, Inc. includes Dr. James Hayward as Chairman, President, and CEO, with Directors Mr. Robert Catell and Ms. Elizabeth Ferguson, and Independent Directors Mr. Scott Anchin, Mr. John Bitzer, and Mr. Joseph Ceccoli.

View full answer

Should I buy, sell or hold Applied DNA Sciences, Inc.?

22-Jun-2025

Compare Applied DNA Sciences, Inc. with Similar Stocks

Microbot Medical, Inc.BiomX, Inc.AquaBounty Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -32.19% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.95

The company has declared Negative results for the last 4 consecutive quarters

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.17

Return on Equity

-122.75%

Price to Book

0.20

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Mar 2026)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-70.89%

6 Months

-89.42%

1 Year

-96.83%

2 Years

-99.95%

3 Years

-88.52%

4 Years

-100.0%

5 Years

-100.0%

Applied DNA Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-6.77%

EBIT Growth (5y)

-32.19%

EBIT to Interest (avg)

-12.95

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.61

Sales to Capital Employed (avg)

1.25

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.48%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.20

EV to EBIT

-0.03

EV to EBITDA

-0.03

EV to Capital Employed

0.04

EV to Sales

0.30

PEG Ratio

Dividend Yield

ROCE (Latest)

-152.67%

ROE (Latest)

-122.75%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (1.41%)

Foreign Institutions

Held by 11 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 66.67% vs 200.00% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 63.98% vs -244.44% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.60",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-13.40",
          "chgp": "84.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.60",
          "val2": "-5.20",
          "chgp": "11.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.70",
          "val2": "-18.60",
          "chgp": "63.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,086.70%",
          "val2": "-23,862.50%",
          "chgp": "2,177.58%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 0.00% vs -84.33% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is -120.59% vs 32.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.10",
          "val2": "2.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.00",
          "val2": "-13.20",
          "chgp": "1.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "6.80",
          "chgp": "-135.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-6.80",
          "chgp": "-120.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,246.20%",
          "val2": "-6,467.20%",
          "chgp": "22.10%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

1.00

0.60

66.67%

Operating Profit (PBDIT) excl Other Income

-2.10

-13.40

84.33%

Interest

0.00

Exceptional Items

-4.60

-5.20

11.54%

Consolidate Net Profit

-6.70

-18.60

63.98%

Operating Profit Margin (Excl OI)

-2,086.70%

-23,862.50%

2,177.58%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 66.67% vs 200.00% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 63.98% vs -244.44% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

2.10

Operating Profit (PBDIT) excl Other Income

-13.00

-13.20

1.52%

Interest

0.00

Exceptional Items

-2.40

6.80

-135.29%

Consolidate Net Profit

-15.00

-6.80

-120.59%

Operating Profit Margin (Excl OI)

-6,246.20%

-6,467.20%

22.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 0.00% vs -84.33% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is -120.59% vs 32.00% in Sep 2024

All Annual Results

Company CV

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc.

Pharmaceuticals & Biotechnology

Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). Its principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon. Its SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA in the field-DNA becomes a solution for supply chain integrity. SigNature DNA is the Company's platform ingredient, at the core of all its security solutions. It provides forensic power and protection for a range of applications. SigNature T DNA is a tagging and authentication system specifically designed for textiles and apparel. DNAnet is a DNA marker that can be used to definitively link evidence and offenders to specific crime scenes and help return stolen or lost property to its rightful owner.

Company Coordinates

Company Details

50 Health Sciences Dr , STONY BROOK NY : 11790-3349

Tel: 1 631 2408800

http://www.adnas.com/

Registrar Details